AKBA
Price
$3.97
Change
+$0.28 (+7.59%)
Updated
Jun 6 closing price
Capitalization
1.04B
54 days until earnings call
CLRPF
Price
$1.56
Change
+$0.01 (+0.65%)
Updated
Jun 6 closing price
Capitalization
469.26M
Interact to see
Advertisement

AKBA vs CLRPF

Header iconAKBA vs CLRPF Comparison
Open Charts AKBA vs CLRPFBanner chart's image
Akebia Therapeutics
Price$3.97
Change+$0.28 (+7.59%)
Volume$8.18M
Capitalization1.04B
Clarity Pharmaceuticals
Price$1.56
Change+$0.01 (+0.65%)
Volume$79.05K
Capitalization469.26M
AKBA vs CLRPF Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. CLRPF commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a StrongBuy and CLRPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (AKBA: $3.97 vs. CLRPF: $1.56)
Brand notoriety: AKBA and CLRPF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 168% vs. CLRPF: 791%
Market capitalization -- AKBA: $1.04B vs. CLRPF: $469.26M
AKBA [@Biotechnology] is valued at $1.04B. CLRPF’s [@Biotechnology] market capitalization is $469.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileCLRPF’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • CLRPF’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than CLRPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 2 TA indicator(s) are bullish.

  • AKBA’s TA Score: 2 bullish, 4 bearish.

Price Growth

AKBA (@Biotechnology) experienced а +31.02% price change this week, while CLRPF (@Biotechnology) price change was +4.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

AKBA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKBA($1.04B) has a higher market cap than CLRPF($469M). AKBA YTD gains are higher at: 108.947 vs. CLRPF (-42.329). AKBA has higher annual earnings (EBITDA): 6.59M vs. CLRPF (-66.98M).
AKBACLRPFAKBA / CLRPF
Capitalization1.04B469M222%
EBITDA6.59M-66.98M-10%
Gain YTD108.947-42.329-257%
P/E RatioN/AN/A-
Revenue185MN/A-
Total Cash113MN/A-
Total Debt54.1MN/A-
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
30
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBA
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
N/A
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
85%
Declines
ODDS (%)
Bearish Trend 27 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LEGN35.003.52
+11.18%
Legend Biotech Corp
CBUS1.660.11
+7.10%
Cibus
EWTX15.240.42
+2.83%
Edgewise Therapeutics
SHBI14.790.33
+2.28%
Shore Bancshares
CDNS296.950.66
+0.22%
Cadence Design Systems

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+7.59%
XERS - AKBA
42%
Loosely correlated
+2.69%
ATOS - AKBA
40%
Loosely correlated
+4.69%
ADAP - AKBA
39%
Loosely correlated
-1.01%
ABOS - AKBA
39%
Loosely correlated
+12.15%
FHTX - AKBA
39%
Loosely correlated
+8.25%
More

CLRPF and

Correlation & Price change

A.I.dvisor tells us that CLRPF and SBHMY have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRPF and SBHMY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRPF
1D Price
Change %
CLRPF100%
+0.32%
SBHMY - CLRPF
24%
Poorly correlated
N/A
BOLD - CLRPF
23%
Poorly correlated
+0.85%
AKBA - CLRPF
21%
Poorly correlated
+7.59%
DOSEF - CLRPF
12%
Poorly correlated
N/A
ACUT - CLRPF
9%
Poorly correlated
+5.20%
More